Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 628

1.

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008516. doi: 10.1002/14651858.CD008516.pub2. Review.

PMID:
22972122
2.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
3.

Aminoadamantanes for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 May 3;(5):CD010125. doi: 10.1002/14651858.CD010125.pub2. Review.

PMID:
24793264
4.

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005642. doi: 10.1002/14651858.CD005642.pub3. Review.

PMID:
24585451
5.

Nitazoxanide for chronic hepatitis C.

Nikolova K, Gluud C, Grevstad B, Jakobsen JC.

Cochrane Database Syst Rev. 2014 Apr 6;(4):CD009182. doi: 10.1002/14651858.CD009182.pub2. Review.

PMID:
24706397
6.

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 Jun 17;(6):CD011132. doi: 10.1002/14651858.CD011132.pub2. Review.

PMID:
24937404
7.

Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS.

Cochrane Database Syst Rev. 2017 Mar 13;3:CD011644. doi: 10.1002/14651858.CD011644.pub2. Review.

PMID:
28285495
8.

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.

Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
24907224
9.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M.

Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
24907225
10.

Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.

Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK.

Cochrane Database Syst Rev. 2013 Dec 2;(12):CD006573. doi: 10.1002/14651858.CD006573.pub3. Review.

PMID:
24297303
11.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747
12.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
13.

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.

Iorio A, Marchesini E, Awad T, Gluud LL.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888. doi: 10.1002/14651858.CD004888.pub2. Review.

PMID:
20091566
14.
15.

Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.

Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR.

Cochrane Database Syst Rev. 2013 Dec 4;(12):CD006803. doi: 10.1002/14651858.CD006803.pub4. Review.

PMID:
24307460
16.

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003617. doi: 10.1002/14651858.CD003617.pub2. Review.

PMID:
23440791
17.

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.

Nagaki M, Shimizu M, Sugihara JI, Tomita E, Sano C, Naiki T, Kimura K, Amano K, Sakai T, Ninomiya M, Kojima T, Katsumura N, Fujimoto M, Moriwaki H.

Aliment Pharmacol Ther. 2009 Aug 15;30(4):343-51. doi: 10.1111/j.1365-2036.2009.04048.x. Epub 2009 May 26.

18.
19.

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM.

Lancet. 2013 Jun 15;381(9883):2100-7. doi: 10.1016/S0140-6736(13)60247-0. Epub 2013 Mar 15.

PMID:
23499440
20.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916

Supplemental Content

Support Center